Overview
BRTX market data
Price History
BRTX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for BRTX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
BioRestorative Therapies Says Lance Alstodt Resigns As President, CEO, Chairman And All Other Positions Effective July 13, 2026; Robert Kristal Resigns As CFO And All Other Positions; Katharyn Field Appointed As CEO, President, And Interim CFOBenzinga · Jul 16, 2026, 9:45 PM
8-K filing — BioRestorative Therapies, Inc. (BRTX)SEC EDGAR · Jul 16, 2026, 9:30 PM
BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc DiseaseBenzinga · Jun 25, 2026, 12:20 PM
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 ResultsBenzinga · May 27, 2026, 2:40 PM
Kaos Capital Acquires 4.9% Of Issued And Outstanding Common Stock Of BioRestorative Therapies; Terms UndisclosedBenzinga · May 27, 2026, 11:47 AM
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataGlobenewswire Inc · May 26, 2026, 3:15 PM
BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc DiseaseBenzinga · May 26, 2026, 3:03 PM
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsGlobenewswire Inc · May 13, 2026, 3:30 PM
BioRestorative Therapies Presents Data Showing MSC-Derived Exosomes Have Source-Specific Functional Signatures For Targeted Therapeutic Applications At The International Society For Cell & Gene Therapy 2026 Annual MeetingBenzinga · May 13, 2026, 3:02 PM